AI Terminal
Zur Rose Group AG
M&A Activity • Aug 17, 2020
1021_rns_2020-08-17_c1e9e2a1-91f3-4948-bb1b-8720f1e0701b.html
M&A Activity
Open in ViewerOpens in native device viewer
News Details
Corporate | 17 August 2020 17:46
Zur Rose Group successfully concluded acquisition of the e-commerce and diabetes activities of Apotal Group
EQS Group-News: Zur Rose Group AG / Key word(s): Takeover
17.08.2020 / 17:46
Press release
Zur Rose Group successfully concluded acquisition of the e-commerce and diabetes activities of Apotal Group
The Zur Rose Group has successfully completed the acquisition of the e-commerce and diabetes activities of Apotal. In the course of this transaction, the Group acquired adbest GmbH, Hilter, Ultrapharm Medicalprodukte GmbH, Bad Rothenfelde, and Dia Plus Minus Handelsgesellschaft mbH, Hilter. For payment of the share portion of the purchase price, Zur Rose Group AG has increased the share capital recorded in the commercial register from 10,380,795 shares by 133,174 shares to 10,513,969 shares with a par value of CHF 30.00 each. The new shares have been issued out of the existing authorised capital.
Investors and analyst contact
Christoph Herrmann, Head of Investor Relations
Email: [email protected], phone: +41 58 810 11 49
Media contact
Lisa Lüthi, Head of Group Communications
Email: [email protected], phone: +41 52 724 08 14
Agenda
19 August 2020 Half-Year Results
21 October 2020 Q3 Trading Update
Zur Rose Group
The Swiss Zur Rose Group is Europe’s largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany’s best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and currently has around nine million active customers in core European markets.
With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform – the Zur Rose ecosystem – it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.
The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.
End of Corporate News
| Language: | English |
| Company: | Zur Rose Group AG |
| Walzmühlestrasse 60 | |
| 8500 Frauenfeld | |
| Switzerland | |
| Phone: | +41 52 724 08 14 |
| Internet: | www.zurrosegroup.com |
| ISIN: | CH0042615283 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1119651 |
| End of News | EQS Group News Service |